Larimar Therapeutics, Inc. (LRMR)
After hours:
| Previous close | 6.69 |
| Open | 6.73 |
| Bid | 6.76 x 400 |
| Ask | 6.83 x 200 |
| Day's range | 6.36 - 6.92 |
| 52-week range | 2.18 - 13.68 |
| Volume | |
| Avg. volume | 523,803 |
| Market cap | 434.523M |
| Beta (5Y monthly) | 0.77 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.12 |
| Earnings date | 12 Nov 2024 - 18 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.14 |
GlobeNewswireLarimar Therapeutics to Participate in Upcoming Investor Conferences
BALA CYNWYD, Pa., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will participate in 1x1 investor meetings at the Wells Fargo Healthcare Conference, taking place September 4-6, 2024 in Boston, MA and the H.C. Wainwright 26th Annual Global Investment Conference, taking place September 9-11, 2024 in
- GlobeNewswire
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Open label extension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024Selected by Food and Drug Administration (FDA) to participate in Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program for nomlabofusp Joined TRACK-FA Neuroimaging Consortium as an industry partner; TRACK-FA collects natural history data to establish disease-specific neuroimaging biomarkers for potential use in clinical trialsPlanning initiation of pharmacok
Simply Wall St.Bullish Larimar Therapeutics Insiders Loaded Up On US$540.7k Of Stock
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
